Comparing Sangamo’s and Amarin’s Revenue Growth



Growth strategy

In its fourth-quarter earnings presentation, Sangamo Therapeutics (SGMO) highlighted its focus on developing innovative genomic medicines targeting conditions in CNS[1.central nervous system] and inherited metabolic diseases and immunology. In its fourth-quarter conference call, the company stated it is deploying approaches in gene therapy and in vivo and ex vivo genomic medicine to advance its research pipeline.

Article continues below advertisement

Sangamo is conducting Phase 1/2 studies on SB-318 and SB-913 for treating MPS (mucopolysaccharidosis) I and MPS II inherited metabolic disorders, respectively. On February 7, the company announced the interim results from the EMPOWERS and CHAMPIONS studies, validating its in vivo genome editing technology.

In its investor presentation, Amarin (AMRN) highlighted the billion-dollar growth opportunity presented by Vascepa’s strong formulary coverage, low costs, and robust clinical data. To learn more, read Vascepa Demand Drove Amarin’s Revenue in Fiscal 2018.

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Wall Street’s projections

Analysts expect Sangamo’s revenue to grow 12.83%, 25.74%, and -21.29% to $95.29 million, $119.81 million, and $94.30 million, respectively, in fiscal 2019, fiscal 2020, and fiscal 2021. In comparison, they expect Amarin’s revenue to grow more, by 59.43%, 55.26%, and 47.30% to $365.43 million, $567.35 million, and $835.73 million.


More From Market Realist